Traws Pharma (STU:0T20) OCF Margin %: 0.00% (As of Mar. 2026)


STU:0T20 Traws Pharma Inc STU:0T20
48 GF Score
Price €6.05
GF Value €90.75
! 4 Warning Signs
View Full Analysis

What is Traws Pharma OCF Margin %?

Traws Pharma STU:0T20 48 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates STU:0T20 with a GF Score™ of 48/100 and a GF Value™ of €90.75. The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Traws Pharma ranks worse than 74.77% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Traws Pharma's Cash Flow from Operations for the three months ended in Mar. 2026 was €-2.23 Mil. Traws Pharma's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Traws Pharma's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Traws Pharma's current OCF Yield % is -117.52%.

The historical rank and industry rank for Traws Pharma's OCF Margin % or its related term are showing as below:

STU:0T20' s OCF Margin % Range Over the Past 10 Years
Min: -13182.3   Med: -5118.21   Max: -285.12
Current: -556.29

During the past 13 years, the highest OCF Margin % of Traws Pharma was -285.12%. The lowest was -13182.30%. And the median was -5118.21%.

STU:0T20's OCF Margin % is ranked worse than
74.77% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs STU:0T20: -556.29

Traws Pharma OCF Margin % Related Terms

Traws Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Traws Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma OCF Margin % Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,623.00 -7,221.60 -7,943.96 -13,171.76 -651.70

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,488.68 -218.73 0.00 0.00 0.00

STU:0T20 vs CVM, CRIS, QNCX: OCF Margin % Comparison

For the Biotechnology subindustry, Traws Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Traws Pharma's OCF Margin % falls into.


STU:0T20
48GF Score
Traws Pharma Inc STU:0T20
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Traws Pharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-15.53/2.383
=-651.70 %

Traws Pharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.228/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Traws Pharma (STU:0T20) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Traws Pharma and its competitors. According to the industry distribution chart, Traws Pharma ranks #717 out of 959 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Traws Pharma's OCF Margin % too high?
Traws Pharma's current OCF Margin % is 0.00%. Based on the distribution chart, Traws Pharma ranks #717 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Traws Pharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's OCF Margin % compare to CVM and CRIS?
According to the Biotechnology industry distribution chart, Traws Pharma ranks #717 out of 959 companies for OCF Margin %. This places Traws Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Traws Pharma and its competitors. Traws Pharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Traws Pharma (STU:0T20) has a current OCF Margin % of 0.00%. The stock's GF Value™ is €90.75, compared to a current price of €6.05 — trading 93.3% below its estimated fair value. The current OCF Margin % is 0.00%. Traws Pharma's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Traws Pharma (STU:0T20), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (STU:0T20) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of €6.05 is trading 93.3% below its estimated GF Value™ of €90.75.

Key valuation signals for STU:0T20:

  • OCF Margin %: 0.00%
  • GF Value™: €90.75 vs. price of €6.05 (93.3% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the STU:0T20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Other Exchanges TRAW:USA
Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
48GF Score

Get the complete analysis for STU:0T20

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.05
Price
€90.75
GF Value